Death events co-reported with NOACs and warfarin in FAERS
| Drug | Total cases (n) | Deaths (n) | Deaths (%) | χ2* | p Value* | PRR (95% CI) |
| Dabigatran | 46 250 | 6989 | 15.11 | 185.2 | 3.61e−42 | 0.838 (0.817 to 0.860) |
| Rivaroxaban | 64 512 | 6318 | 9.79 | 359.4 | 3.72e−80 | 1.293 (1.259 to 1.328) |
| Apixaban | 17 789 | 1693 | 9.52 | 145.8 | 1.43e−33 | 1.331 (1.269 to 1.395) |
| Edoxaban | 755 | 53 | 7.02 | 21.2 | 4.18e−06 | 1.804 (1.391 to 2.340) |
| All NOACs | 1 28 267 | 14 917 | 11.63 | 70.0 | 6.05e−17 | 1.089 (1.067 to 1.111) |
| Warfarin | 1 53 911 | 19 493 | 12.67 | NA | NA | 1.000 |
*When compared with warfarin.
FAERS, Food and Drug Administration Adverse Event Reporting System; NA, not applicable; NOACs, non-vitamin K antagonist oral anticoagulants; PRR, proportional reporting ratio.